Sanofi and its partner Regeneron have secured Japanese approval for Dupixent (dupilumab) as the first targeted treatment for bullous pemphigoid, a rare, chronic skin disease that primarily affects elderly patients. The Ministry of Health, Labour and Welfare granted marketing and manufacturing authorization on March 24 2026, expanding Dupixent’s indications in Japan to a seventh therapeutic area.
The approval was based on the LIBERTY‑BP‑ADEPT phase 2/3 study, which enrolled 106 adults with moderate‑to‑severe bullous pemphigoid. At week 36, 18% of patients receiving Dupixent achieved sustained disease remission compared with 4% of placebo recipients. Treatment‑related adverse events occurred in 26% of the Dupixent group versus 15% in the placebo group, with conjunctivitis the most common event (4%).
This milestone addresses an unmet medical need in Japan, where existing therapies are limited and often involve systemic immunosuppression. Dupixent’s mechanism—blocking interleukin‑4 and interleukin‑13 signaling—provides a non‑immunosuppressive option, potentially improving safety and tolerability for older patients. The approval also positions Sanofi to capture a new segment of the dermatology and immunology market, which is sizable given the prevalence of bullous pemphigoid in the aging population.
Sanofi’s recent financial performance underscores the strategic value of this approval. In Q4 2025, the company reported €11.3 billion in revenue, with Dupixent sales contributing €4.2 billion. The addition of bullous pemphigoid to Dupixent’s portfolio is expected to further strengthen the biologics pipeline and enhance revenue diversification in the immunology space.
Strategically, the approval reinforces Sanofi’s focus on expanding its immunology platform. By adding a first‑in‑class therapy for bullous pemphigoid, Sanofi can deepen its presence in dermatology, potentially increase market share, and create new growth opportunities in a niche but high‑need therapeutic area.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.